

# Jian Xu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4419850/publications.pdf>

Version: 2024-02-01

20  
papers

525  
citations

933447

10  
h-index

794594

19  
g-index

20  
all docs

20  
docs citations

20  
times ranked

598  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. , 2020, 206, 107438.   |      | 117       |
| 2  | Advances and challenges in the treatment of esophageal cancer. Acta Pharmaceutica Sinica B, 2021, 11, 3379-3392.   | 12.0 | 101       |
| 3  | Nanoparticle systems for cancer vaccine. Nanomedicine, 2019, 14, 627-648.  | 3.3  | 85        |
| 4  | Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget, 2018, 9, 5459-5472.  | 1.8  | 47        |
| 5  | Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy. Pharmacological Research, 2017, 126, 66-76.  | 7.1  | 28        |
| 6  | An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy. Oncotarget, 2015, 6, 26322-26334.   | 1.8  | 23        |
| 7  | A novel protein kinase inhibitor IMB-YH-8 with anti-tuberculosis activity. Scientific Reports, 2017, 7, 5093.  | 3.3  | 21        |
| 8  | EGFR-targeting, $\hat{\imath}^2$ -defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis. Acta Pharmacologica Sinica, 2018, 39, 1777-1786. | 6.1  | 20        |
| 9  | Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors. Biomolecules, 2020, 10, 973.  | 4.0  | 16        |
| 10 | Substituted 4-oxo-crotonic acid derivatives as a new class of protein kinase B (PknB) inhibitors: synthesis and SAR study. RSC Advances, 2017, 7, 4763-4775.   | 3.6  | 12        |
| 11 | Enediyne-activated, EGFR-targeted human $\hat{\imath}^2$ -defensin 1 has therapeutic efficacy against non-small cell lung carcinoma. Laboratory Investigation, 2018, 98, 1538-1548.  | 3.7  | 10        |
| 12 | CDK11p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target. Cell Cycle, 2019, 18, 452-466.   | 2.6  | 10        |
| 13 | Nanocarrierâ€delivered small interfering <sc>RNA</sc> for chemoresistant ovarian cancer therapy. Wiley Interdisciplinary Reviews RNA, 2021, 12, e1648.   | 6.4  | 8         |
| 14 | Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. Advanced Materials, 2021, 33, e2103114.  | 21.0 | 6         |
| 15 | Intensive fibrosarcoma-binding capability of the reconstituted analog and its antitumor activity. Drug Delivery, 2018, 25, 102-111.  | 5.7  | 5         |
| 16 | Enhancing the Therapeutic Efficacy of Gefitinib in Human Non-Small-Cell Lung Cancer through Drug Combination. Molecular Pharmaceutics, 2021, 18, 1397-1407.  | 4.6  | 5         |
| 17 | Antibodyâ€Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer. Advanced Biology, 2022, , 2101065.   | 2.5  | 4         |
| 18 | Albuminâ€Mediated Delivery of Bioactive Peptides for Pancreatic Cancer Therapy. Advanced Therapeutics, 2020, 3, 2000003.   | 3.2  | 3         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Loss of ID3 in pancreatic cancer cells increases DNA damage without impairing MDC1 recruitment to the nuclear foci. <i>Cancer Communications</i> , 2022, 42, 269-272.  | 9.2 | 3         |
| 20 | Novel Humanized Mesothelin-Expressing Genetically Engineered Mouse Models Underscore Challenges in Delivery of Complex Therapeutics to Pancreatic Cancers. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2082-2092. | 4.1 | 1         |